高强度训练联合碳酸氢钠补充对健康人群机体衰老的影响

注册号:

Registration number:

ChiCTR2500103896 

最近更新日期:

Date of Last Refreshed on:

2025-12-08 16:17:58 

注册时间:

Date of Registration:

2025-06-06 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

高强度训练联合碳酸氢钠补充对健康人群机体衰老的影响

Public title:

Effect of high-intensity training combined with sodium bicarbonate supplementation on aging in healthy people

注册题目简写:

English Acronym:

研究课题的正式科学名称:

高强度训练联合碳酸氢钠补充对健康人群机体衰老的影响

Scientific title:

Effect of high-intensity training combined with sodium bicarbonate supplementation on aging in healthy people

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

刘雅 

研究负责人:

谢亘青 

Applicant:

Ya Liu 

Study leader:

Genqing Xie 

申请注册联系人电话:

Applicant telephone:

+86 155 8081 5436

研究负责人电话:

Study leader's
telephone:

+86 181 6360 2595

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

359223031@qq.com

研究负责人电子邮件:

Study leader's E-mail:

genqingxie@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

湖南省长沙市开福区湘雅路87号

研究负责人通讯地址:

湖南省湘潭市岳塘区书院路100号

Applicant address:

No.87, Xiangya Road, Kaifu District, Changsha City, Hunan Province

Study leader's address:

No.100, Shuyuan Road, Yuetang District, Xiangtan City, Hunan Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中南大学湘雅医院

Applicant's institution:

Xiangya hospital of central south university

研究负责人所在单位:

湘潭市第一人民医院

Affiliation of the Leader:

The first people's hospital of Xiangtan hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2025052005;2025110701

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

湘潭市第一人民医院伦理委员会

Name of the ethic committee:

Ethics Committee of Xiangtan First People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025-05-20 00:00:00

伦理委员会联系人:

杨杰

Contact Name of the ethic committee:

Jie Yang

伦理委员会联系地址:

湖南省湘潭市岳塘区书院路100号

Contact Address of the ethic committee:

No. 100, Shuyuan Road, Yuetang District, Xiangtan City, Hunan Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 732 5866 9195

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

湘潭市第一人民医院

Primary sponsor:

Xiangtan First People's Hospital

研究实施负责(组长)单位地址:

湖南省湘潭市岳塘区书院路100号

Primary sponsor's address:

No. 100, Shuyuan Road, Yuetang District, Xiangtan City, Hunan Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

湖南

市(区县):

Country:

China

Province:

Hunan

City:

单位(医院):

湘潭市第一人民医院

具体地址:

湖南省湘潭市岳塘区书院路100号

Institution
hospital:

Xiangtan First People's Hospital

Address:

No. 100, Shuyuan Road, Yuetang District, Xiangtan City, Hunan Province

经费或物资来源:

国家级课题

Source(s) of funding:

National Funding

研究疾病:

衰老  

Target disease:

Aging

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

主要目的 本研究旨在通过随机平行对照实验设计,系统评估高强度训练联合口服碳酸氢钠干预对健康受试者衰老生理的影响。 次要目的 评估高强度训练对健康人群衰老状态的独立影响。 探讨碳酸氢钠补充对高强度训练后衰老影响的协同作用。  

Objectives of Study:

Main purpose This study aims to systematically evaluate the effects of high-intensity training combined with oral sodium bicarbonate intervention on the aging physiology of healthy subjects through a randomized parallel controlled experimental design. Secondary purpose Evaluate the independent effects of high-intensity training on the aging status of healthy individuals. Exploring the synergistic effect of sodium bicarbonate supplementation on aging after high-intensity training

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.入组前3个月内参与过任何干预性临床研究(包括药物/器械/生物制剂试验); 2.重大系统性疾病史 (需满足当前仍存在临床意义),详情如下: 循环系统疾病(如冠心病、高血压Ⅱ级以上、严重心律失常) 代谢内分泌疾病(糖尿病、甲状腺功能亢进/减退症等,泌尿系统疾病(慢性肾脏病3期及以上),神经系统疾病(癫痫、卒中后遗症等),免疫系统异常(原发性/获得性免疫缺陷、自身免疫性疾病),其他系统性疾病(血液系统、呼吸系统、精神类疾病等); 3.肾功能限制要求(血清肌酐需采用标准化检测方法) CockcroftGault公式计算肌酐清除率(CrCl)<80mL/min; CrCl = [(140-年龄) × 体重(kg)] / [0.814 × Scr(µmol/L)] 4.临床检查异常, 入选时存在以下任何临床显著异常(研究者判定):体格检查异常体征墩、ECG病理性改变 、实验室检测值超出正常范围20%以上 、生命体征持续偏离基线值 ; 5.其他不宜入选情形:经研究团队综合评估存在影响研究完整性或受试者安全的特殊情形 。

Exclusion criteria:

1. Participated in any interventional clinical study (including drug/device/biologics trial) within 3 months prior to enrollment; 2. History of major systemic disease (subject to clinical significance), details as follows: Circulatory diseases (e.g., coronary heart disease, hypertension over level II, severe arrhythmias) Metabolic endocrine diseases (diabetes, hyperthyroidism/hypothyroidism, etc.), urological diseases (chronic kidney disease stage 3 and above), neurological diseases (epilepsy, stroke sequelae, etc.), immune system abnormalities (primary/acquired immunodeficiency, autoimmune diseases), other systemic diseases (hematological, respiratory, psychiatric diseases, etc.); 3. Requirements for renal function limitation (serum creatinine needs to be tested by standardized testing methods) The CockcroftGault formula calculates creatinine clearance (CrCl) < 80 mL/min; CrCl = [(140-age) × body weight (kg)] / [0.814 × Scr(μmol/L)] 4. Abnormal clinical examination, any of the following clinically significant abnormalities (as judged by the investigator) at the time of enrollment: abnormal signs of physical examination, pathological changes in ECG, laboratory test values exceeding the normal range by more than 20% and persistent deviation of vital signs from the baseline value; 5. Other circumstances that are not suitable for selection: There are special circumstances that affect the integrity of the study or the safety of subjects as comprehensively assessed by the research team.

研究实施时间:

Study execute time:

From 2025-05-10 00:00:00 To 2025-11-10 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-06-14 00:00:00 To 2025-06-28 00:00:00

干预措施:

Interventions:

组别:

碳酸氢钠组

样本量:

20

Group:

Sodium bicarbonate group

Sample size:

干预措施:

口服含碳酸氢钠的碱性水

干预措施代码:

Intervention:

Oral administration of alkaline water containing sodium bicarbonate

Intervention code:

组别:

对照组

样本量:

20

Group:

Control group

Sample size:

干预措施:

口服不含碳酸氢钠的中性水

干预措施代码:

Intervention:

Oral administration of neutral water without sodium bicarbonate

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

湖南 

市(区县):

 

Country:

China

Province:

Hunan

City:

单位(医院):

湘潭市第一人民医院 

单位级别:

三甲 

Institution
hospital:

Xiangtan First People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

实验室检测指标

指标类型:

次要指标

Outcome:

Laboratory test indicators

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

人体测量学指标

指标类型:

次要指标

Outcome:

Anthropometric index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

皮肤状态综合评估

指标类型:

主要指标

Outcome:

Skin condition assessment

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

运动心肺测试

指标类型:

次要指标

Outcome:

Exercise cardiopulmonary test

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肌肉量与质量评估

指标类型:

次要指标

Outcome:

Muscle mass and quality assessment

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肌肉功能测试

指标类型:

次要指标

Outcome:

Muscle function test

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

认知功能

指标类型:

次要指标

Outcome:

Cognitive assessment

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

骨密度和体成分分析

指标类型:

次要指标

Outcome:

Bone density and body composition analysis

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

皮肤组织活检

指标类型:

次要指标

Outcome:

Skin tissue biopsy

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肌肉组织活检

指标类型:

次要指标

Outcome:

Muscle tissue biopsy

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

粪便宏基因组

指标类型:

附加指标

Outcome:

Fecal metagenome

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

全基因组甲基化芯片测序

指标类型:

附加指标

Outcome:

Whole genome methylation chip sequencing

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血清蛋白质组学

指标类型:

附加指标

Outcome:

Serum proteomics

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血清脂质组学

指标类型:

附加指标

Outcome:

Serum lipidomics

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血清代谢组学

指标类型:

附加指标

Outcome:

Serum metabolomics

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

全血单细胞组学

指标类型:

附加指标

Outcome:

Whole blood single-cell omics

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

影像学检查

指标类型:

次要指标

Outcome:

Imaging examination

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

其它必要衰老指标

指标类型:

次要指标

Outcome:

Other necessary indicators of aging

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

标本中文名:

肌肉

组织:

Sample Name:

Muscle

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

标本中文名:

皮肤

组织:

Sample Name:

Skin

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

标本中文名:

粪便

组织:

Sample Name:

Feces

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 60 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由统计师采用SAS 9.4软件生成分层区组随机序列 每个分层组合单独生成随机序列 区组长度设置为4以保证分配平衡

Randomization Procedure (please state who generates the random number sequence and by what method):

Generate stratified block random sequences using SAS 9.4 software by statisticians Generate random sequences separately for each hierarchical combination Set the block length to 4 to ensure balanced allocation

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

本研究采用双盲设计,即受试者和研究者(以及对试验结果进行评估的研究人员)在整个试验过程中均不清楚治疗分组情况。

Blinding:

Double-blind: Participants and investigators are blinded to group assignment.

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

原始数据将于论文发表后公开,试验的原始数据上传至中国临床试验注册中心的ResMan临床试验公共管理平台,http://www.medresman.org

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The raw data will be made publicly available upon publication of the manuscript through the ResMan clinical trial public management platform of the Chinese Clinical Trial Registry (ChiCTR) at http://www.medresman.org.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-06-06 17:06:18